A pharmaceutical product called TT-10, which spurs proliferation of heart muscle cells, was thought to offer promise to treat heart attacks. In a mouse heart-attack model several years ago, intraperitoneal injection of TT-10 at first promoted proliferation of heart muscle cells and showed declines in the size of the dead area of heart muscle. However, these early improvements were followed by worsened cardiac function at later time points. Now researchers show that a different delivery method, nanoparticle-mediated, slow-release of TT-10, enhances the potency and durability of TT-10 treatment for repair of heart muscle in the mouse heart-attack model.
from Top Health News -- ScienceDaily https://ift.tt/3pEHsst
Subscribe to:
Post Comments (Atom)
Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO
However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...
-
The IT major further said the Ebit margin for the current quarter is expected to be between 20.5-21 per cent from Home Page https://ift.tt...
-
Here's a look at some of the companies whose shares are expected to trade actively in Friday's session - from Home Page http://bit...
-
Private sector ports and logistics company Adani Ports and Special Economic Zone Ltd. (APSEZ) is acquiring the residual 25% stake in Adani K...
No comments:
Post a Comment